Shorter Trastuzumab Course Still Effective.
Reducing the duration of trastuzumab treatment may be beneficial for women with HER2-positive breast cancer: In the phase III PERSEPHONE trial, women who received the drug for 6 months had a similar rate of disease-free survival as women on a 12-month course, but were half as likely to stop treatment due to cardiac side effects.